Magnetic Resonance Image Guided Radiotherapy (MRIgRT) course

Key information

Next course dates

22-23 September 2025, closing date for registrations 18th August 2025

Location

BLB Sutton, SM2 5PT
See Sutton map at the bottom of our contacts page.

This course is organised by The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London.

Course outline

An opportunity to broaden your understanding of the capabilities and potential of MRI guidance in radiotherapy planning and treatment verification. We invite you to join us to hear from leading practitioners in the field, develop skills and share knowledge with other professionals involved in MRI in radiotherapy.

This two day course aims to improve understanding of MRIgRT, focusing on the knowledge and skills required to support current and future needs in radiotherapy.

The development of MRI in radiotherapy planning involves close communication with radiology and radiotherapy professionals. This course is aimed at all professionals involved in or interested in MRI for radiotherapy, including radiographers, physicists and clinicians.

Course Organisers: Professor Helen McNair, Ms Erica Scurr, Dr Shaista Hafeez, Miss Trina Herbert, and Professor Uwe Oelfke

"Great overall knowledge for all professions interested in MRI - extremely informative."
– Therapeutic Radiographer and course attendee

Course overview

The course will include taught and practical workshops to:

Improve understanding of the basic principles of MRI
Build foundation skills to support the increase in demand for MRI simulation
Develop practical skills
Learn about current clinical pathways and the latest research developments

The practical demonstrations will include:

MR simulation, image acquisition and interpretation, RT set up and safety.
Sequence and parameter manipulation
Adaptive workflow on the MR Linac

Provisional lecture list

The clinical need for MR in radiotherapy
Image contrast, Resolution and Factors affecting signal-to-noise
MR Simulation
MR planning workflow
MR-CT fusion planning
Image fusion and dosimetry
Safety considerations
Regional MR in RT – Pelvis,
Regional MR in RT, Abdomen (liver and pancreas)
Regional MR in RT, Breast
Managing motion (4D)
MR in Brachytherapy
MR Linac QA
Diffusion Weighted Imaging (DWI) principles and applications
Functional imaging

Programme draft

Previous comments from attendees

“I have now significantly more knowledge of potential for MRI in radiotherapy, its benefits and drawbacks.” – Clinical Oncologist

“MRI in radiotherapy planning is a lot more complicated than I thought. Highlighted that we would be crazy to do more MRI without an MRI physicist in the trust.” – Radiotherapy Physicist

“Excellent overview of MRI and how it is and will be used in the future.” – Radiotherapy Physicist

“Collaboration between diagnostic and Therapy radiographers is vital in MR planning.” – Therapeutic Radiographer

Accommodation

Accommodation is available in local hotels, details can be supplied upon request.

Further information

For further details on up to date course content call +44 (0)20 8661 3704 or email Cheryl Taylor.

Latest ICR News

Silencing gene may combat formation of radiation-induced scar tissue, a new study reveals

04/06/25

A new study suggests that silencing CXCL12, a gene involved in tissue scarring and repair, could help reduce the formation of scar tissue that can caused by radiotherapy. Ultimately, the researchers hope this approach could improve treatment outcomes for breast cancer patients undergoing radiotherapy and reconstructive surgery.

See full story

ASCO 2025: One-time cell therapy offers long-term survival hope for patients with advanced melanoma

02/06/25

A one-time immunotherapy treatment using a patient’s own immune cells has shown long-lasting benefit for people with advanced melanoma, a serious form of skin cancer, according to new five-year follow-up data from a pivotal clinical trial.

See full story

ASCO 2025: Next-generation breast cancer drug targets tumours before they have a chance to grow

01/06/25

A powerful new drug for advanced breast cancer can be used to treat emerging tumours, months before they have a chance to grow, helping to keep patients well for longer and delaying the need for later-line therapies including chemotherapy. Results of a global study, funded by AstraZeneca and co-led by researchers at The Institute of Cancer Research, London, The Royal Marsden NHS Foundation Trust and Institut Curie, Paris, were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on 1 June 2025.

See full story

Professor Nick Turner (right) in his lab at the Institute of Cancer Research, London

ASCO 2025: New therapy improves survival in advanced breast cancer and delays need for chemotherapy

31/05/25

A promising new therapy can help patients with aggressive advanced breast cancer live longer and delays the need for further chemotherapy, new research has shown. Final results of the INAVO120 study, led by an international team of researchers including scientists at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, have demonstrated the potential of the new therapy combination for targeting PIK3CA-mutated hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer – a common form of the disease.

See full story